Payne S F, Lemp G F, Rutherford G W
AIDS Office, Department of Public Health, San Francisco, CA 94102.
J Acquir Immune Defic Syndr (1988). 1990;3 Suppl 1:S14-7.
To evaluate survival for AIDS patients diagnosed with Kaposi's sarcoma (KS), we calculated survival for 1,015 patients reported in San Francisco between July 1981 and December 31, 1987, representing 22% of total patients reported. These patients had a definitive initial diagnosis of KS, and developed no other diseases within 3 months of diagnosis. Patients were followed prospectively through December 31, 1988. All patients evaluated in this study were men. Survival was evaluated for subgroups based on age, race and ethnicity, year of diagnosis, and transmission category. The median survival for patients diagnosed with KS alone was 17.0 months, with a 5-year survival rate of 8.7%. Poorer prognosis was found for patients with older age at diagnosis and with later year of diagnosis. Proportional hazards analysis indicated that age (p less than 0.001) and year of diagnosis (p less than 0.05) were significant independent predictors of survival, while race or ethnicity and risk group were not.
为评估被诊断患有卡波西肉瘤（KS）的艾滋病患者的生存率，我们计算了1981年7月至1987年12月31日在旧金山报告的1015例患者的生存率，这些患者占报告的全部患者的22%。这些患者有明确的KS初始诊断，且在诊断后3个月内未患其他疾病。对患者进行前瞻性随访至1988年12月31日。本研究中评估的所有患者均为男性。根据年龄、种族和民族、诊断年份以及传播类别对亚组的生存率进行了评估。仅被诊断患有KS的患者的中位生存期为17.0个月，5年生存率为8.7%。发现诊断时年龄较大和诊断年份较晚的患者预后较差。比例风险分析表明，年龄（p<0.001）和诊断年份（p<0.05）是生存率的显著独立预测因素，而种族或民族以及风险组则不是。
